Randomized trials comparing ABVD or regimen of equivalent efficacy alone with treatment that includes radiation therapy.
| Author . | Control Therapy . | Experimental Therapy . | Number . | Disease Control Outcome* . | Overall Survival* . |
|---|---|---|---|---|---|
| * Results reported for control group followed by experimental group | |||||
| Abbreviations: ABVD: doxorubicin (Adriamycin®), bleomycin, vinblastine and dacarbazine; COPP: cyclophosphamide, Oncovin® (vincristine), prednisone, procarbazine; IF RT: involved-field radiation; EF RT: extended-field radiation; CMT: combined modality therapy; EFS: event-free survival; FFP: freedom from progression; ns: not stated | |||||
| Laskar19 | ABVD + IF RT | ABVD | 99 | 8-yr EFS: 97% vs 94%; P = 0.29 | 8-yr: 100% vs 98%; P = 0.26 |
| Nachman20 | COPP-ABV + IF RT | COPP-ABV | 215 | 3-yr EFS: 97% vs 91%; P ns | 3-yr: 100% vs 100%; P ns |
| Straus21 | ABVD + EF RT | ABVD | 152 | 5-yr FFP: 86% vs 81%; P = 0.61 | 5-yr: 97% vs 90%; P = 0.08 |
| Meyer22 | EF RT (favorable cohort; n = 64) or CMT (unfavorable cohort; n = 139): ABVD + EF RT | ABVD | 399 | 5-yr FFP: 93% vs 87%; P = 0.006 | 5-yr: 94% vs 96%; P = 0.4 |
| Author . | Control Therapy . | Experimental Therapy . | Number . | Disease Control Outcome* . | Overall Survival* . |
|---|---|---|---|---|---|
| * Results reported for control group followed by experimental group | |||||
| Abbreviations: ABVD: doxorubicin (Adriamycin®), bleomycin, vinblastine and dacarbazine; COPP: cyclophosphamide, Oncovin® (vincristine), prednisone, procarbazine; IF RT: involved-field radiation; EF RT: extended-field radiation; CMT: combined modality therapy; EFS: event-free survival; FFP: freedom from progression; ns: not stated | |||||
| Laskar19 | ABVD + IF RT | ABVD | 99 | 8-yr EFS: 97% vs 94%; P = 0.29 | 8-yr: 100% vs 98%; P = 0.26 |
| Nachman20 | COPP-ABV + IF RT | COPP-ABV | 215 | 3-yr EFS: 97% vs 91%; P ns | 3-yr: 100% vs 100%; P ns |
| Straus21 | ABVD + EF RT | ABVD | 152 | 5-yr FFP: 86% vs 81%; P = 0.61 | 5-yr: 97% vs 90%; P = 0.08 |
| Meyer22 | EF RT (favorable cohort; n = 64) or CMT (unfavorable cohort; n = 139): ABVD + EF RT | ABVD | 399 | 5-yr FFP: 93% vs 87%; P = 0.006 | 5-yr: 94% vs 96%; P = 0.4 |